Primary outcomes: post-bronchodilator FEV1 and total CRQ and sputum characteristics before and after mometasone and placebo for the whole group (n = 60)
| Pre-ICS | Post-ICS | p value(pre v post ICS) | Pre-placebo | Post-placebo | p value(pre v post placebo) | p value(net improvement) | |
|---|---|---|---|---|---|---|---|
| FEV1, forced expiratory volume in 1 second; CRQ, Chronic Respiratory Disease Questionnaire; ICS, inhaled corticosteroid; IL-8, interleukin 8; ECP, eosinophilic cationic protein. | |||||||
| Values are mean (SE) except †geometric mean (log SE), ‡median (IQR). | |||||||
| FEV1 (l) | 1.25 (0.07) | 1.25 (0.07) | 0.4 | 1.17 (0.07) | 1.15 (0.07) | 0.6 | 0.35 |
| FEV1 (l) post-bronchodilator | 1.34 (0.08) | 1.37 (0.08) | 0.31 | 1.25 (0.07) | 1.24 (0.08) | 0.77 | 0.36 |
| CRQ total | 4.15 (0.15) | 4.4 (0.16) | 0.015 | 4.15 (0.17) | 4.54 (0.17) | 0.018 | 0.8 |
| Total cell count 106/g sputum | 2.8 (0.4) | 3.7 (1.1) | 0.5 | 3.7 (0.6) | 4.9 (1.4) | 0.27 | 0.66 |
| Eosinophils (%)† | 2.20 (0.07) | 1.58 (0.08) | 0.014 | 2.32 (0.09) | 1.96 (0.09) | 0.25 | 0.38 |
| Neutrophils (%)‡ | 77.9 (61–89) | 80.3 (62–90) | 0.21 | 77.9 (63–89) | 75.1 (67–87) | 0.63 | 0.22 |
| Macrophages (%)‡ | 14.5 (7–31) | 11.8 (8–30) | 0.12 | 14.2 (5–25) | 14.9 (7–20) | 0.53 | 0.42 |
| Bronchial epithelial cells (%)‡ | 1.3 (0.5–2.6) | 1.6 (0.4–3.7) | 0.15 | 1.4 (0.2–1.9) | 1.1 (0.4–3.1) | 0.08 | 0.56 |
| Lymphocytes (%)‡ | 0.4 (0.18–1.0) | 0.4 (0–0.8) | 0.5 | 0.4 (0.70.1–0.8) | 0.5 (0.2–0.9) | 0.69 | 0.85 |
| Histamine (ng/g) † | 49 (0.09) | 50 (0.09) | 0.6 | 59 (0.08) | 51 (0.09) | 0.79 | 0.35 |
| IL-8 (ng/g)† | 109 (0.06) | 95 (0.05) | 0.21 | 118 (0.06) | 123 (0.06) | 0.13 | 0.13 |
| ECP (ng/g)† | 1115 (0.07) | 1021 (0.08) | 0.4 | 982 (0.09) | 1060 (0.09) | 0.12 | 0.09 |